How to Add Peptide Therapy to an Existing Clinic: A Revenue Expansion Guide for Chiropractors, Med Spas, and Wellness Practices
The Revenue Expansion Opportunity Every Existing Clinic Owner Should Evaluate
For a chiropractor who has built a solid patient base, a med spa that has established itself in aesthetic services, or a wellness practice already offering IV therapy and health coaching, the peptide therapy category represents one of the most natural and commercially significant service expansion opportunities in 2026. Peptides are one of several services worth weighing; for the others, see our guide to regenerative health services for existing clinics.
For the full peptide therapy clinic business case (including market data, FDA reclassification update, and financial model), see The Peptide Therapy Clinic Business Model.
Altos Consulting Group (ACG) is a consulting firm that helps entrepreneurs open cash-pay clinics across 13 clinic types and helps existing clinics add services such as peptide therapy. ACG is not a medical practice: it does not provide care, and every clinical decision rests with independent, state-licensed providers. Our team has launched hundreds of clinics.
Altos Consulting Group works with existing clinic owners through clinic growth consulting. We track which peptides a 503A pharmacy can lawfully compound today, compound by compound, on our page on how to open a peptide clinic.
Which Existing Clinic Types Are Best Positioned
Chiropractic Practices
The chiropractic patient managing musculoskeletal issues, chronic pain, and recovery from injury overlaps significantly with the recovery-focused peptide patient profile. But BPC-157 and TB-500, often sold for tissue repair and inflammation, are not on the 503A Bulks List or FDA-approved; since October 30, 2026 a temporary HHS enforcement discretion policy covers compounding them only under strict conditions, so a chiropractic peptide program is built on compounds that do not depend on it, BPC-157 and TB-500 stay off the menu, and the medical director sets every protocol. The clinical conversation is natural, the patient motivation is clear, and the cross-referral dynamic is built into the existing relationship.
Med Spas
The med spa patient demographic investing in appearance and aesthetic longevity is naturally receptive to peptide services framed within a longevity and biological optimization context. A med spa that introduces non-injectable GHK-Cu or Sermorelin, at the medical director's discretion, extends its existing premium positioning into clinical territory that complements the aesthetic services the patient already receives. The route decides GHK-Cu: non-injectable forms are compoundable under FDA's interim policy, and injectable GHK-Cu cannot be compounded today (October 2026), whatever a supplier says. Still planning the med spa itself? Our team can be your med spa consultant, from market validation to opening day.
IV Therapy and Wellness Practices
An IV therapy clinic or wellness practice already administering NAD+ infusions or other IV-based nutritional therapies has established the clinical environment, nursing staff infrastructure, and patient trust that makes adding injectable protocols built on lawfully compoundable peptides a natural operational extension. The patient comfortable receiving IV therapy from the clinic's staff can be highly convertible to a peptide protocol conversation.
The Compliance Requirements for Existing Clinics
Medical Director Requirements
If the existing clinic does not already have a medical director with prescribing authority appropriate to the peptide compounds the practice intends to offer, establishing that relationship is the first compliance step. Chiropractors generally cannot prescribe compounded peptides on their own authority: they require a collaborating physician or, in states with full practice authority, a nurse practitioner with prescribing scope covering the intended protocols. Stem cell procedures go further: collecting and reimplanting the tissue generally falls outside chiropractic scope, so a physician performs or directly oversees them under a collaborative arrangement structured with healthcare counsel. For that path, see our guide to adding stem cell therapy to a chiropractic practice.
Protocol Development and Documentation
Clinical protocols for each peptide compound offered must be developed, reviewed, and approved by the medical director before the first patient is treated. Patient consent forms must address the regulatory status of the compounds and the nature of the clinical relationship. Documentation standards for peptide prescriptions must be established and consistently followed. For each of these in detail, see our guide to peptide clinic compliance.
Supplier Relationships
Compounding pharmacy relationships must be established before peptide compounds can be offered to patients, and compounding itself runs under the FD&C Act's compounding provisions. ACG clients get pre-negotiated pricing on clinical supplies, materials and equipment that is unavailable outside the network, a difference that compounds every month. ACG's clinic growth consulting for existing clinics includes supplier introduction as a core deliverable, made at no additional charge through our clinic supplier network.
The Revenue Impact
A med spa that introduces Sermorelin and NAD+ programs to its existing patients, at the medical director's discretion, can add recurring protocol revenue alongside its existing appointment revenue. For planning, monthly recurring revenue is the number of enrolled patients times the average monthly program fee, before costs, with the fee set for the clinic's own market.
ACG's clinic growth consulting for existing clinic owners begins with an assessment of your clinic, and pricing is discussed once the scope is clear. Planning another location instead? We can help you start another wellness clinic. To start the conversation, book a free 30-minute strategy call.
The First Six Months After Adding Peptide Services: What to Expect and How to Manage It
The first six months after an existing clinic adds peptide therapy services is the period that determines whether the expansion builds momentum or stalls, and the dynamics of this period are different from what many clinic owners expect based on their experience opening or growing other service lines. Understanding what the first six months actually looks like, and what the operational responses to common challenges are, is the practical intelligence that separates a successful peptide expansion from a disappointing one.
Months one and two are usually slower than projected. The existing patient base takes time to become aware of and curious about the new services. The clinical team is still developing confidence and fluency with the new protocols. The referral channels (including the physician referral relationships that are often among the highest-quality patient sources for peptide therapy) take time to develop even when active outreach begins immediately. A clinic that enrolls far fewer new peptide patients in month one than it projected is not failing. It is experiencing the normal ramp pattern of a service expansion, and the appropriate response is maintaining the marketing and outreach strategy with patience rather than pivoting to a different approach before the initial strategy has had time to work.
Months three and four are when the compounding patient is the most commercially important variable. The patients who enrolled in month one are approaching their first protocol renewal point: a check-in and lab monitoring on the schedule the medical director sets. The outcome of these early renewals is the most important data point available about whether the clinical program is working. A high renewal rate at that first check-in suggests patients value the program enough to continue. A low one suggests a clinical or patient communication problem that must be diagnosed and addressed before the expansion can build sustainable momentum.
A common cause of early-stage renewal challenges in peptide therapy expansions is not protocol failure. It is expectation misalignment: patients who were enrolled without a clear articulation of what the first months would look like clinically, what they would feel, and what the monitoring data would measure. A patient who entered on Sermorelin expecting to feel dramatically different right away, and feels mostly the same weeks later, has an expectations problem that the clinical team can correct with honest monitoring review, but only if the monitoring appointment happens before the patient has quietly decided not to renew. An early check-in call (not a billing call, a genuine clinical check-in) is the single most important retention tool in the first months of a peptide expansion.
Months five and six are when organic referrals begin arriving if the clinical program is working. The peptide therapy patient who is satisfied with the program talks about it in the specific communities where the peptide therapy patient demographic is active. These referrals are qualitatively different from advertising-generated leads: they arrive with specific questions, a clear understanding of what they are seeking, and a baseline of trust established by the person who referred them. A clinic that is receiving organic referrals from its first cohort of peptide patients at month five has built something that compounds, and the appropriate investment at this stage is deepening the clinical program quality and monitoring infrastructure rather than increasing advertising spend.
Questions About Adding Peptide Therapy to an Existing Clinic
Can a chiropractor offer peptide therapy to patients?
Not independently, as chiropractors do not have prescribing authority for compounded medications in most U.S. states. However, a chiropractic clinic can add peptide therapy services through a collaborative arrangement with a licensed medical professional (a physician or nurse practitioner with appropriate prescribing scope) who provides clinical oversight and prescription authority for the peptide protocols.
How long does it take to add peptide therapy to an existing clinic?
With the right compliance framework, supplier relationships, and protocol documentation in place, an existing clinic can begin offering peptide therapy services within weeks of beginning the expansion process.
Which peptide services are the easiest to add to an existing clinic?
Growth hormone secretagogue protocols built on Sermorelin, which 503A pharmacies can compound, are typically the most accessible entry point for existing clinic expansion because they require only injectable administration infrastructure that many clinics already have, the patient motivation is broadly applicable, and the retention dynamics can produce recurring revenue from the first protocol cycle. The Ipamorelin/CJC-1295 combination, often sold alongside it, cannot be compounded today (October 2026), whatever a supplier says, and every protocol is the medical director's call.
How do you add a peptide program to an existing practice?
Start with a medical director who has prescribing authority for the compounds you plan to offer, and have that prescriber write and approve every protocol before the first patient. Add a licensed 503A compounding pharmacy, consent forms that state each compound's regulatory status, and a documentation workflow, then train staff and plan marketing within the ad platforms' rules. Build the menu on what a pharmacy can lawfully compound without HHS's temporary peptide policy: sermorelin qualifies, ipamorelin does not, and BPC-157, which depends on that policy, stays off the menu (October 2026).
How do clinics onboard a team to a new peptide program?
Train the team on the medical director's written protocols, on what each role may do under your state's scope-of-practice rules (including whether a nurse practitioner needs a collaborative agreement or supervision), and on the consent and documentation workflow. Staff should describe a compound's regulatory status accurately and leave what it may do for a patient to the prescriber, because under the FTC's health products guidance, health claims must be backed by competent and reliable scientific evidence. As part of clinic growth consulting, ACG plans clinic staff training.
How do clinics document peptide therapy in the chart?
A compounded peptide needs a valid prescription for an identified individual patient (section 503A of the FD&C Act), so the chart should hold the prescriber's evaluation and rationale, the signed consent naming the compound's regulatory status, any labs the medical director orders, and the prescription itself: the compound, dose, route, schedule and dispensing pharmacy. Follow-up visits, any change the prescriber makes and any adverse event go in the same record.
What are the eligibility requirements to start peptide therapy?
There is no universal checklist: whether a patient is a candidate is a clinical decision the prescribing clinician makes after an evaluation, often with labs the clinician orders. A compounded peptide can be dispensed only on a valid prescription for that individual patient, and only for a compound a 503A pharmacy can lawfully make; state rules govern how the evaluation may be done, in person or by telehealth. If the evaluation is done by telehealth, the prescriber generally needs a license in the patient's state, and mapping the states a virtual practice can serve is part of our telehealth strategy consulting.
How do I market a peptide therapy clinic?
Mostly through organic search, referrals and reviews, because paid advertising is limited: under Google's healthcare and medicines policy, advertisers must apply before running prescription drug ads, and platforms restrict ads in this category. Describe services and each compound's regulatory status rather than results, since health claims need competent and reliable scientific evidence. See how we plan the strategy for peptide clinic marketing. Marketing execution is a separate engagement.
Written by Nova, Senior Content Strategist at Altos Consulting Group.
